Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy

Carlo Visco, Theodoros P. Vassilakopoulos, Kay Oliver Kliche, Gianpaolo Nadali, Simonetta Viviani, Valeria Bonfante, L. Jeffrey Medeiros, P. Notti, George Z. Rassidakis, Prema Peethambaram, Richard Wilder, Thomas Witzig, Massimo Gianni, Gianni Bonadonna, Giovanni Pizzolo, Gerassimos A. Pangalis, Fernando Cabanillas, Andreas H. Sarris

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P < 0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.

Original languageEnglish (US)
Pages (from-to)2085-2092
Number of pages8
JournalLeukemia and Lymphoma
Volume45
Issue number10
DOIs
StatePublished - Oct 1 2004

Keywords

  • Hodgkin's disease
  • Interleukin-10
  • Prognostic factors
  • Radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy'. Together they form a unique fingerprint.

  • Cite this

    Visco, C., Vassilakopoulos, T. P., Kliche, K. O., Nadali, G., Viviani, S., Bonfante, V., Medeiros, L. J., Notti, P., Rassidakis, G. Z., Peethambaram, P., Wilder, R., Witzig, T., Gianni, M., Bonadonna, G., Pizzolo, G., Pangalis, G. A., Cabanillas, F., & Sarris, A. H. (2004). Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leukemia and Lymphoma, 45(10), 2085-2092. https://doi.org/10.1080/10428190410001712234